Preeminent gastroenterology practice management company selects Fujifilm’s industry-leading portfolio of endoscopic imaging solutions

FUJIFILM Medical Systems U.S.A., Inc., a leading provider of endoscopic imaging and endosurgical solutions, and part of the greater Fujifilm Healthcare portfolio, announces that United Digestive’s gastroenterologists are now using Fujifilm’s portfolio of 700 series advanced endoscopes and Eluxeo Imaging Systems.

The decision to partner with Fujifilm and adapt their innovative endoscopic imaging technologies is in line with United Digestive’s mission to support their gastroenterologists by providing them with the clinical and operational support that empowers them to focus on the patient and deliver the absolute best care.

“The investment we make in our technology is also an investment we make in the health and well-being of our patients,” said John Suh, M.D., MPH, Chief Medical Officer for United Digestive. “Our partnership with Fujifilm is extremely positive, and we’ve received outstanding feedback from our clinicians on ELUXEO’s strikingly impressive image resolution, as well as the performance they’ve experienced across the variety of Fujifilm endoscopes.”

“Their hands-on approach to implementation ensured each of our physicians was fully supported in order to deliver uninterrupted quality patient care,” added Suh. “Fujifilm’s commitment to providing exceptional service and support was a key factor as to why we selected them as the exclusive vendor of choice for all of our 15 endoscopy centers.”

“We’re appreciative of the confidence United Digestive has instilled in Fujifilm by selecting us as their partner for endoscopic imaging solutions,” says Taisuke Fujita, General Manager of FUJIFILM Medical Systems U.S.A., Inc.—Endoscopy. “We’ve seen time and time again that collaboration drives innovation, and we’re grateful to work with an esteemed gastroenterology practice that is committed to leveraging superior technology that will provide better patient diagnosis and treatment that could inevitably save lives.”

Fujifilm’s collaboration with United Digestive comes shortly after FUJIFILM Medical Systems U.S.A., Inc.’s announcement of achieving several global milestones and initiatives to advance the field of endoscopy and endoscopic health. Some of Fujifilm’s latest developments in its global endoscopy business include artificial intelligence advancements, high-tech image capture, advanced data processing and notably, the launch of twelve new endoscopes, a variety of which the United Digestive is now using to enhance their affiliated clinical practices.

In the United States, colorectal cancer is the third leading cause of cancer-related deaths in men and in women, and the second most common cause of cancer deaths when men and women are combined. Although the rate of people being diagnosed with colon or rectal cancer each year has dropped overall since the mid-1980s, mainly because more people are getting screened and changing their lifestyle-related risk factors, the illness is expected to cause about 52,980 deaths during 2021. The industry encourages that individual’s schedule appropriate and regular screenings, as many colorectal cancers can be prevented through regular screenings, and when found early, colorectal cancer is highly treatable.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It’s ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm’s in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit  

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $22.1 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:


Danielle Brown